Inpharma 1484 - 23 Apr 2005

Cardiac resynchronisationimproves symptoms in HF,

dyssynchronyCardiac resynchronisation, in addition to standard

pharmacological therapy, improves the symptomsassociated with heart failure (HF) and dyssynchrony to agreater extent than standard pharmacological therapyalone, according to results from a study conducted inEurope.*

In the multicentre CARE-HF** study, 813 patients withHF and dyssynchrony were randomised to receivestandard pharmacological therapy alone (n = 404) or incombination with resynchronisation.

The composite of all-cause mortality or unplannedhospitalisation due to a major cardiovascular event wasobserved in a significantly smaller proportion of patientsin the cardiac resynchronisation group than in the groupthat received standard therapy alone (39% vs 55%). Asignificantly smaller proportion of patients whounderwent cardiac resynchronisation than standardtherapy recipients experienced unplannedhospitalisation for a cardiovascular event (31% vs 46%).

Treatment with cardiac resynchronisation wasassociated with a significantly lower mortality rate thantreatment with standard therapy alone (20% vs 30%).The risk of mortality or hospitalisation due to worseningheart failure was significantly lower among the patientswho underwent cardiac resynchronisation than in thosewho received standard therapy alone. At 90 days,symptoms and quality of life were significantly improvedamong the patients in the cardiac resynchronisationgroup, compared with those in the group that receivedstandard therapy alone.* This study was supported by Medtronic.** Cardiac Resynchronization – Heart Failure

Cleland JGF, et al. The effect of cardiac resynchronization on morbidity andmortality in heart failure. New England Journal of Medicine 352: 1539-1549, No.15, 14 Apr 2005 800967842

1

Inpharma 23 Apr 2005 No. 14841173-8324/10/1484-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved